Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Brain Neoplasms 6Recurrence 3Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Neoplasm Metastasis 2Melanoma 2Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Obesity 1Neuroblastoma 1Motor Activity 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Hepatitis 1Health Behavior 1Glioblastoma 1Fibrosis 1Cognition Disorders 1Child Behavior 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Behavior 1

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × Spermine Synthase × Clear all
NCT05429190 2023-11-29

Validation of SMS Protocol for HCC Screening in High-risk Patients

Erasmus Medical Center

Unknown
470 enrolled
Gastrointestinal

Fibrosis, Hepatitis, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡